PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
 
AAPS PharmSciTech. 2007 September; 8(3): E13–E19.
Published online 2007 July 13. doi:  10.1208/pt0803053
PMCID: PMC2750549

Formulation and optimization of porous osmotic pump-based controlled release system of oxybutynin

Abstract

The aim of the current study was to design a porous osmotic pump-based drug delivery system for controlled release of oxybutynin. The porous osmotic pump contains pore-forming water-soluble additives in the coating membrane, which after coming in contact with water, dissolve, resulting in an in situ formation of a microporous structure. The dosage regimen of oxybutynin is one 5-mg tablet 2 to 3 times a day. The plasma half-life ranges from ~2 to 3 hours. Hence, oxybutynin was chosen as a model drug with an aim to develop a controlled release system for a period of 24 hours. Linear and reproducible release similar to that of Ditropan XL was achieved for optimized formulation (f2>50) independent of hydrodynamic conditions. The effect of different formulation variables, namely, ratio of drug to osmogent, membrane weight gain, and level of pore former on the in vitro release was studied. Cellulose acetate (CA) was used as the semipermeable membrane. It was found that drug release rate increased with the amount of osmogent because of the increased water uptake, and hence increased driving force for drug release. Oxybutynin release was inversely proportional to the membrane weight gain; however, directly related to the level of pore former, sorbitol, in the membrane. This system was found to deliver oxybutynin at a zero-order rate for 20 hours. The effect of pH on drug release was also studied. The optimized formulations were subjected to stability studies as per International Conference on Harmonisation (ICH) guidelines and formulations were stable after a 3 month study.

Keywords: Osmotic system, oxybutynin, osmogent, cellulose acetate, pore former

Full Text

The Full Text of this article is available as a PDF (293K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Speers M, Bonnano C. Economic aspects of controlled drug delivery. In: Mathiowitz E, editor. Encyclopedia of Controlled Drug Delivery. New York, NY: Wiley; 1999. pp. 341–347.
2. Santus G, Baker WR. Osmotic drug delivery: a review of patent literature. J Control Release. 1995;35:1–21. doi: 10.1016/0168-3659(95)00013-X. [Cross Ref]
3. Theeuwes F. Elementary osmotic pump. J Pharm Sci. 1975;64:1987–1991. doi: 10.1002/jps.2600641218. [PubMed] [Cross Ref]
4. Zentner GM, McClelland GA, Sutton SC. Controlled porosity solubility-and resin-modulated osmotic, drug delivery systems for release of diltiazem hydrochloride. J Control Release. 1991;16:237–244. doi: 10.1016/0168-3659(91)90047-H. [Cross Ref]
5. Zentner M, Rork GS, Himmelstein KJ. Osmotic flow through controlled porosity films: an approach to delivery of water-soluble compounds. J Control Release. 1985;2:217–229. doi: 10.1016/0168-3659(85)90047-1. [Cross Ref]
6. Zentner GM, Rork GS, Himmelstein KJ, inventors. Controlled porosity osmotic pump. US patent 4 968 507. November 6, 1990.
7. Herbig SM, Cardinal JR, Korsmeyer RW, Smith KL. Asymmetric-membrane tablet coatings for osmotic drug delivery. J Control Release. 1995;35:127–136. doi: 10.1016/0168-3659(95)00028-7. [Cross Ref]
8. Goldenberg MM. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder. Clin Ther. 1999;21:634–642. doi: 10.1016/S0149-2918(00)88316-2. [PubMed] [Cross Ref]
9. Douchamps J, Derenne F, Stockis A, et al. The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol. 1988;35:515–520. doi: 10.1007/BF00558247. [PubMed] [Cross Ref]
10. Brunton LL, editor. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill; 2006.
11. Gupta SK, Sathyan G. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol. 1999;39:289–296. [PubMed]
12. Monograph 7089. Oxybutynin Chloride. In: Budavari S, ed.The Merck Index. 12th ed. Whitehouse Station, NJ: Merck & Co; 1996.
13. Byrn SR, Xu W, Newman AW. Chemical reactivity in solid-state pharmaceuticals: formulation implications. Adv Drug Deliv Rev. 2001;48:115–136. doi: 10.1016/S0169-409X(01)00102-8. [PubMed] [Cross Ref]
14. Verma RK, Kaushal AM, Garg S. Development and evaluation of extended release formulations of isosorbide mononitrate based on osmotic technology. Int J Pharm. 2003;263:9–24. doi: 10.1016/S0378-5173(03)00360-0. [PubMed] [Cross Ref]
15. Zentner GM, Rork GS, Himmelstein KJ. The controlled porosity osmotic pump. J Control Release. 1985;1:269–282. doi: 10.1016/0168-3659(85)90003-3. [Cross Ref]
16. Moore JW, Flanner HH. Mathematical comparison of dissolution profiles. Pharm Technol. 2007;20:64–74.

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists